Percutaneous Implantation of Autologous Bone Marrow Osteoprogenitor Cells as Treatment of Bone Avascular Necrosis Related to Sickle Cell Disease

Philippe Hernigou*, 1, Gilsasio Daltro2, Paolo Filippini1, Martin Mukisi Mukasa3, Olivier Manicom3
1 Department of Orthopaedic Surgery, 51 Avenue du Maréchal de Lattre de Tassigny, 94010 cedex Créteil, France
2 Hospital Edgar Santos, University Federal of Bahia, Salvador, Brazil
3 Hôpital de Point à Pitre – Guadeloupe, France

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 706
Abstract HTML Views: 535
PDF Downloads: 263
Total Views/Downloads: 1504
Unique Statistics:

Full-Text HTML Views: 464
Abstract HTML Views: 380
PDF Downloads: 183
Total Views/Downloads: 1027

Creative Commons License
© Hernigou et al.; Licensee Bentham Open.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited.

* Address correspondence to this author at the Service de Chirurgie Orthopédique et Traumatologique, Hospital Henri Mondor, 51 avenue du Maréchal de Lattre de Tassigny, 94010 cedex Créteil, France; Tel: 00 33 1 49 81 26 01; Fax: 00 33 1 49 81 26 08; E-mail:


The treatment of bone a vascular necrosis is a big challenge considering the youthfulness of the patients involved by necrosis in sickle cell disease and the importance of the generated disability. A vascular osteonecrosis is an epiphysis pathology which could be treated by joint replacement with success, however, multiple surgical procedures are mostly necessary during the patient’s life with a hazardous long term functional results. The treatment by autologous bone marrow grafting is an effective alternative which preserve the native joint. Using this mini-invasive high technology surgical treatment in early stages, a joint replacement could be avoided in many patients.

Keywords: Avascular osteonecrosis, marrow grafting, mesenchymal stem cell, bone regeneration.